Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03506646 · ClinicalTrials.gov registry record · NA

Dietary Nitrate Supplementation and Thermoregulation

A NA study of Peripheral Arterial Disease and Peripheral Artery Disease, sponsored by University of Nebraska.

Completed
Registry status
NA
Development phase
11
Enrollment target
1
Study location

NCT03506646: Completed NA study of Peripheral Arterial Disease and Peripheral Artery Disease, sponsored by University of Nebraska.

NCT03506646 is a NA study of Peripheral Arterial Disease and Peripheral Artery Disease that has completed, run by University of Nebraska. The registered enrollment target is 11 participants, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03506646, a NA study of Peripheral Arterial Disease and Peripheral Artery Disease, has completed, sponsored by University of Nebraska.

COMPLETED
Registry status
NA
Development phase
11 participants
Enrollment target
1
Study location

Study Summary

This is a double-blinded, randomized, crossover design study to assess the effects of dietary nitrate supplementation (beetroot juice) on peripheral artery disease (PAD) patients (ages 50-85) diagnosed with Fontaine stage I or II PAD (as determined by vascular surgeon at UNMC). Exclusion criteria include: 1) experience severe claudication (leg pain) at rest or tissue loss due to PAD (Fontaine stage III and IV), 2) have limited walking capacity due to conditions other than PAD, 3) are already supplementing with a form of dietary nitrate, or 4) have an allergy to beetroot juice. Subjects will be required to visit the lab 3 times and will be randomized to receive either the supplement or the placebo for the 2nd and 3rd visits. There will be a washout period of 14 days between the 2nd and 3rd visits. Visit 1 will take approximately 2 hours and the 2nd/3rd visits will take approximately 1.5 hours. Total experimentation period will last approximately 15 days. Visit 1 will consist of non-invasive baseline testing including assessment of endothelial function (flow-mediated dilation by ultrasound imaging), maximal walking capacity (Gardner treadmill protocol), leg function (near-infrared spectroscopy, time to onset claudication, blood flow to lower extremities), and body core temperature (rectal thermometer). Visits 2 and 3 will require consumption of either the supplement or placebo. The same tests from the baseline measurements will be performed for visits 2 and 3. There will be a recommended fourth visit, albeit not required, to review study results.

Primary Outcome

Endothelial function will be assessed using flow mediated dilation to measure vasodilation in the brachial artery (baFMD).

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Beet root juice

Study Locations (1)

Nebraska

  • University of Nebraska at Omaha - Omaha

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2018-09-05
Est. Completion 2022-12-15
Phase NA
University of Nebraska

407 total trials

What the finished NCT03506646 record still lists

NCT03506646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 4,206-participant average among 79 other Peripheral Arterial Disease trials with a reported enrollment target (100% lower).

The record links to 2 conditions, with Peripheral Arterial Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03506646 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT03506646 about?

NCT03506646 is a clinical study titled "Dietary Nitrate Supplementation and Thermoregulation". This is a double-blinded, randomized, crossover design study to assess the effects of dietary nitrate supplementation (beetroot juice) on peripheral artery disease (PAD) patients (ages 50-85) diagnosed with Fontaine stage I or II PAD (as determined by vascular surgeon at UNMC). Exclusion criteria in...

What is the current status of trial NCT03506646?

This trial is currently completed. It is a NA study. The enrollment target is 11 participants. The study started on 2018-09-05. Estimated completion is 2022-12-15.

What conditions does trial NCT03506646 study?

This clinical trial studies the following conditions: Peripheral Arterial Disease, Peripheral Artery Disease.

What interventions are being tested in trial NCT03506646?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Beet root juice (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03506646?

This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03506646 being conducted?

This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Peripheral Arterial Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03506646's enrollment target sits among peer trials

11 75th of 79 higher than 5 of 79 other Peripheral Arterial Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Peripheral Arterial Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03114462 · 11 participants · Phase 1

    Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

  • NCT06039709 · 11 participants · Phase 1

    Sonodynamic Therapy in Patients With Recurrent GBM

  • NCT06425380 · 11 participants · NA

    Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy

  • NCT06472661 · 11 participants · Early Phase 1

    FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03506646, the US trial registry maintained by the National Library of Medicine. NCT03506646 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.